Ja­cob­son Pharma to tap biosim­i­lars mar­ket

BioSpectrum (Asia) - - Company News -

Ja­cob­son Med­i­cal and Joy­ful As­cent Lim­ited, sub­sidiaries of Ja­cob­son Pharma Cor­po­ra­tion Lim­ited have en­tered into a Li­cens­ing Frame­work Agree­ment and a Cap­i­tal In­crease Agree­ment with Shang­hai Hen­lius Biotech Inc. Shang­hai Hen­lius is a sub­sidiary of Shang­hai Fo­sun Phar­ma­ceu­ti­cal Co., Ltd, that is a tech­no­log­i­cal leader in re­search and de­vel­op­ment of biosim­i­lar an­ti­body drugs in China. These col­lab­o­ra­tive agree­ments will help Ja­cob­son Group and Shang­hai Hen­lius forge a strate­gic plat­form to quickly tap into the fast grow­ing biosim­i­lar mar­ket in Hong Kong and cer­tain emerg­ing ASEAN mar­kets. Ja­cob­son Pharma is a lead­ing com­pany en­gaged in the re­search, de­vel­op­ment, pro­duc­tion, mar­ket­ing and sale of generic drugs and pro­pri­etary medicines. Un­der the Li­cens­ing Frame­work Agree­ment, Ja­cob­son Med­i­cal will be granted an ex­clu­sive right to de­velop and mar­ket a pro­pri­ety biosim­i­lar prod­uct of Shang­hai Hen­lius in Hong Kong and Ma­cau for a pe­riod of 10 years, along­side a right of first ne­go­ti­a­tion to­wards en­ter­ing into a defini­tive agree­ment to com­mer­cial­ize the prod­uct in cer­tain emerg­ing mar­kets within ASEAN do­mains.

The prod­uct is the sec­ond mon­o­clonal an­ti­body de­vel­oped by Shang­hai Hen­lius with a gen­eral name of Re­com­bi­nant Hu­man­ized Anti-Her2 Mon­o­clonal An­ti­body In­jec­tion, which be­longs to the biosim­i­lar ver­sion of Tras­tuzumab.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.